ReviewFrontiers in immunology2026
Decoding the PTM code of cGAS-STING in gastric cancer: from innate DNA sensing to precision combination therapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Significance of cGAS-STING Signaling in Response to Oncogenic Viruses.Cell biochemistry and function · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cGAS-STING pathway represents a crucial component of innate immune responses and has been increasingly recognized as a pivotal regulatory mechanism governing gastric cancer progression and therapeutic resistance. This comprehensive review synthesizes current knowledge regarding the mechanisms through which Post-Translational Modifications (PTMs) modulate the activity, stability, and subcellular localization of cGAS and STING proteins, encompassing phosphorylation, ubiquitination, acetylation, SUMOylation, and palmitoylation. These PTMs function as pivotal regulators that maintain the delicate balance between immune activation and suppression within the tumor microenvironment, directly influencing tumor immune evasion, proliferation, and metastatic potential. Furthermore, we critically examine the dual role of the cGAS-STING pathway in gastric cancer, highlighting its context-dependent anti-tumor and pro-tumor effects. We also investigate potential therapeutic strategies targeting post-translational modifications to restore or potentiate cGAS-STING signaling, which could substantially enhance the efficacy of chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Our comprehensive analysis underscores the substantial prognostic and therapeutic promise of PTM-directed interventions for gastric cancer management, providing a valuable foundation for future mechanistic research and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.